Grumabix (Abiraterone Acetate)

Grumabix is indicated for patients with metastatic castration‑resistant prostate cancer (mCRPC) who have previously received hormonal therapy. It is used as part of a comprehensive treatment plan to inhibit androgen production and help control tumor progression.

• Combined with prednisone to mitigate mineralocorticoid excess.
• Prescribed after failure of first‑line androgen deprivation therapy.
• Utilized in patients with documented disease progression despite chemotherapy.
• May be considered for patients with rising prostate‑specific antigen (PSA) levels.
• Integrated into multidisciplinary oncology care for advanced prostate cancer.

Side effects of Grumabix vary in frequency and severity. Common reactions are usually mild to moderate, while serious events require immediate medical attention.

Common

• Fatigue or weakness.
• Fluid retention leading to swelling of the legs or ankles.
• Elevated liver enzymes indicating hepatic stress.
• Decreased potassium levels (hypokalemia).
• Increased blood pressure.

Serious

• Severe liver injury or hepatitis.
• Adrenal insufficiency causing crisis.
• Cardiovascular events such as heart failure.
• Severe hypertension resistant to treatment.
• Acute kidney injury or renal failure.

Before initiating Grumabix, clinicians should evaluate patient history and monitor specific parameters throughout therapy. Precautions help reduce the risk of adverse outcomes.

• Assess liver function tests prior to and during treatment.
• Monitor blood pressure regularly; manage hypertension promptly.
• Check electrolyte levels, especially potassium and sodium.
• Evaluate for signs of adrenal insufficiency; provide glucocorticoid support as needed.
• Use caution in patients with pre‑existing heart or kidney disease.
• Discuss potential risks with patients who have a history of thromboembolic events.
• Ensure concurrent prednisone therapy to reduce mineralocorticoid side effects.

Grumabix may interact with several drug classes, influencing its efficacy or safety profile. Awareness of these interactions supports optimal patient management.

Avoid

• Strong CYP3A4 inducers such as rifampin, carbamazepine, or phenytoin, which can lower abiraterone levels.
• Concurrent use of other androgen synthesis inhibitors without medical supervision.
• Medications that significantly raise blood pressure without appropriate monitoring.

Use with caution

• Antifungal agents (e.g., ketoconazole, itraconazole) that inhibit CYP3A4 and may increase exposure.
• Anticoagulants, as hypertension may affect bleeding risk.
• Diuretics, which can exacerbate electrolyte disturbances.
• NSAIDs, potentially worsening hypertension or renal function.
• Other hormonal therapies that could compound endocrine effects.